Display options
Cite
Zaid AN, Ghanem M, Shweiki D, et al. In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients. Ther Clin Risk Manag. 2016;12:1425-1432doi: 10.2147/TCRM.S110727.
Zaid, A. N., Ghanem, M., Shweiki, D., Shtewi, H., Shaheen, R., Al Helaly, S., Khayyat, Z., Al Ramahi, R., & Zyoud, S. H. (2016). In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients. Therapeutics and clinical risk management, 121425-1432. https://doi.org/10.2147/TCRM.S110727
Zaid, Abdel Naser, et al. "In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients." Therapeutics and clinical risk management vol. 12 (2016): 1425-1432. doi: https://doi.org/10.2147/TCRM.S110727
Zaid AN, Ghanem M, Shweiki D, Shtewi H, Shaheen R, Al Helaly S, Khayyat Z, Al Ramahi R, Zyoud SH. In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients. Ther Clin Risk Manag. 2016 Sep 19;12:1425-1432. doi: 10.2147/TCRM.S110727. eCollection 2016. PMID: 27703364; PMCID: PMC5036554.
Copy Download .nbib Format: NLM
Share it on

Ther Clin Risk Manag. 2016 Sep 19;12:1425-1432. doi: 10.2147/TCRM.S110727. eCollection 2016.

In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients.

Therapeutics and clinical risk management

Abdel Naser Zaid, Masshour Ghanem, Dua'a Shweiki, Hala Shtewi, Raja' Shaheen, Sondos Al Helaly, Zeina Khayyat, Rowa'a Al Ramahi, Sa'ed H Zyoud

Affiliations

  1. Department of Pharmacy, Faculty of Medicine & Health Sciences, An-Najah National University, Nablus.
  2. Pharmacare Ltd, Ramallah, Palestine.

PMID: 27703364 PMCID: PMC5036554 DOI: 10.2147/TCRM.S110727

Abstract

OBJECTIVES: The objectives of this study were to evaluate the general quality of the most prescribed products of valsartan (VL; alone or in combination) and to evaluate their efficacy and safety among Palestinian population through in vivo postmarketing surveillance.

PATIENTS AND METHODS: The first part was pharmacopeial quality control assay, including dissolution, disintegration, friability, and weight uniformity for VL. The second part was a 3-month cardiology clinics, observational, postmarketing surveillance pilot study that included 103 hypertensive patients who were prescribed 80 mg or 160 mg of VL as monotherapy or combination therapy. The end points were reduction in blood pressure (BP) and the rate of incidence of adverse effects (AEs) at weeks 4 and 8.

RESULTS: According to our quality control tests, all VL products showed high-quality standards according to the international guidelines. A reduction in BP was observed at weeks 4 and 8, and no significant difference was observed between the strengths of 80 mg and 160 mg. Higher BP reduction was observed after the use of combination therapy. Moreover, VL was well tolerated; most of the AEs were of mild-to-moderate intensity. In general, the most frequently reported AEs included headache (17.5%), dizziness (11.75%), and weakness (11.7%). No serious AEs or death cases were reported during the study period.

CONCLUSION: High quality of VL tablet products was used; hence, the observed efficacy and safety results should be related to patient's factors and not due to any product defects or substandard quality. Moreover, VL is an effective treatment for essential hypertension.

Keywords: Palestine; postmarketing; quality control; surveillance; valsartan

References

  1. Adv Ther. 2014 Jul;31(7):762-75 - PubMed
  2. Adv Ther. 2012 Feb;29(2):134-47 - PubMed
  3. Sci Pharm. 2011 Mar;79(1):123-35 - PubMed
  4. J Pharm Pharm Sci. 2006;9(2):169-89 - PubMed
  5. Clin Ther. 1996 Sep-Oct;18(5):797-810 - PubMed
  6. Adv Ther. 2011 Feb;28(2):134-49 - PubMed
  7. J Int Med Res. 1995 Jan-Feb;23(1):61-73 - PubMed
  8. Drugs. 2009;69(17):2393-414 - PubMed
  9. Hosp Pract. 1977 Jan;12(1):119-27 - PubMed
  10. J Hypertens. 2010 Jul;28(7):1356-65 - PubMed
  11. Am Fam Physician. 1999 Jun;59(11):3140-8 - PubMed
  12. East Mediterr Health J. 2013 Jun;19(6):542-6 - PubMed
  13. J Am Soc Hypertens. 2016 Jan;10 (1):55-69.e1 - PubMed
  14. Ann Intern Med. 2008 Jan 1;148(1):16-29 - PubMed
  15. Blood Press Suppl. 2011 Dec;2:13-21 - PubMed
  16. Drugs. 2002;62 Spec No 1:53-64 - PubMed
  17. J Hum Hypertens. 2002 Nov;16(11):795-803 - PubMed

Publication Types